PharmaEngine
4162.TWO
1.71 USD
-0.02
-1.16%
p
Overview
Last close
1.71 usd
Market cap
242.58M usd
52 week high
3.68 usd
52 week low
1.71 usd
Target price
3.82 usd
Valuation
P/E
19.9257
Forward P/E
6.2735
Price/Sales
8.332
Price/Book Value
1.5646
Enterprise Value
96.52M usd
EV/Revenue
3.3273
EV/EBITDA
5.8376
Key financials
Revenue TTM
29.01M usd
Gross Profit TTM
27.36M usd
EBITDA TTM
13.60M usd
Earnings per Share
0.09 usd
Dividend
0.06 usd
Total assets
163.99M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
